FSHR and polycystic ovary syndrome: Cyp19a1 (0.14 ± 0.02 fold) and Fshr (0.03 ± 0.01 fold) gene expression were lower in PCOS group ovaries, consistent with the prior characterization of the LTZ-induced PCOS mouse model [19]; levels of both genes significantly increased after BM-hMSC treatment (Cyp19a1: 0.93 ± 0.11 fold, Fshr: 0.80 ± 0.09 fold; Fig. 5b, c).